Colony Capital, Inc. Securities Litigation

According to the Complaint, it is alleged that the Merger Consideration and the Proposed Transaction are fundamentally unfair to Plaintiff and the other common shareholders of Colony. It is alleged the Board has agreed to a deal where Colony shareholders receive no premium for their shares and end up with a diluted ownership stake in a combined company that will be dragged down by the recent financial and corporate governance problems that have plagued the NorthStar entities.

See Case Details »

Misonix, Inc. Securities Litigation

According to the law firm press release, the lawsuit alleges throughout the Class Period Misonix made false and/or misleading statements and/or failed to disclose that: (1) deficiencies existed in Misonix\\\\'s internal controls over financial reporting; and (2) as a result, Defendants\\\\' statements about Misonix\\\\'s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

See Case Details »

Heartware International, Inc. Securities Litigation (2016)

According to the Complaint, on June 27, 2016, Medtronic and the Company announced that they had entered into an Agreement and Plan of Merger dated June 27, 2016 (\"Merger Agreement\"), by which Medtronic, through its affiliate Medtronic Acquisition Corp. (\"Merger Sub\") commenced a tender offer to acquire all of the outstanding shares of HeartWare for $58.00 per share in cash (\"Proposed Transaction\"). The Proposed Transaction is valued at approximately $1.1 billion and is expected to close during Medtronic\'s second fiscal quarter ending October 28, 2016. The Proposed Transaction was unanimously approved by the Board.

See Case Details »

Sagent Pharmaceuticals, Inc. Securities Litigation

According to a law firm's press release, on July 10, 2016, Sagent's Board of Directors (the "Board") caused Sagent to enter into an agreement and plan of merger with Nichi-Iko Pharmaceutical Co., Ltd. and its subsidiary Shepard Vision, Inc. (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, stockholders of Sagent will receive $21.75 per share in cash. The Complaint alleges that on August 1, 2016, Defendants issued materially incomplete and misleading disclosures in the Solicitation/Recommendation Statement filed on Schedule 14D-9 (the "Solicitation Statement") filed with the United States Securities and Exchange Commission ("SEC") in connection with the Proposed Transaction. According to the Complaint, the Solicitation Statement is deficient and misleading in that it fails to provide adequate disclosure of all material information related to the Proposed Transaction.

See Case Details »

Hatteras Financial Corp. Securities Litigation

According to the law firm press release, on April 11, 2016, the Company announced it had entered into an Agreement and Plan of Merger ("Merger Agreement") under which Annaly would acquire all of the outstanding shares of Hatteras through a tender offer (the "Tender Offer"). Following the Tender Offer, if more than two-thirds of the outstanding Hatteras common stock (including Hatteras shares owned by Annaly and its subsidiaries) had been tendered, Hatteras would be merged with and into an Annaly subsidiary in a "second-step" merger under the Maryland General Corporation Law, which would permit completion of the Merger without a shareholder vote if Annaly acquired the minimum two-thirds of Hatteras outstanding stock.

See Case Details »